Photo: Google Images
In South Africa will test an HIV vaccine. The study, called HVTN 702, will take part 5400 men and women, this test will become the largest of all trials of HIV vaccines that has ever taken place in South Africa. Know that every day in the country, more than 1,000 people are infected with HIV, and in 2014, the virus had infected approximately 2.4 million people.
Anthony Fauci (Anthony S. Fauci), Director of the National Institute of allergic and infectious diseases explained that even a vaccine with moderate efficacy will help to significantly reduce the incidence of HIV infection.
Trials of an HIV vaccine was conducted in 2009 in Thailand. Observations of the study participants continued for 3.5 years after vaccination. Then it was shown that its efficiency was 31%. And South Africa will experience a modified vaccine, which has been adapted to more effectively fight the virus, common in this region. The procedure of vaccination has also been modified to increase the effectiveness of vaccinations against HIV. The test will take place in 15 districts of the country, and their results will be known in 2020.
A few months before ended HVTN 702 HVTN 100 study. It on 252 participants evaluated the safety of a new Protocol of vaccination.
Patients will be administered two experimental vaccines: vaccine ALVAC-HIV (Sanofi Pasteur), created on the basis of the smallpox Canaries, the genome of which is integrated three genes encoding the HIV proteins and two-component subunit vaccine containing the viral surface protein gp120 and the adjuvant, enhancing the development of the immune response (GSK).
Some participants will receive placebo, and others will be administered the vaccine. For a year they make 5 injections. All participants will be under the close supervision of experts, in addition to vaccination they will be offered standard tools to prevent HIV infection. In that case, if they are infected with HIV, they will be assigned the necessary treatment, and also describe the precautions that will reduce the risk of transmitting the virus to others.